Ken Griffin Aerie Pharmaceuticals Inc Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$6.37 - $15.23 $870,046 - $2.08 Million	136,585 Added 148.53%	228,542 $3.46 Million
Q2 2022 Aug 15, 2022	SELL	$4.95 - $9.16 $3,836 - $7,099	-775 Reduced 0.84%	91,957 $690,000
Q1 2022 May 16, 2022	BUY	$5.64 - $9.8 $324,587 - $563,999	57,551 Added 163.59%	92,732 $844,000
Q4 2021 Feb 14, 2022	SELL	$7.02 - $13.33 $4.36 Million - $8.27 Million	-620,400 Reduced 94.63%	35,181 $246,000
Q3 2021 Nov 15, 2021	BUY	$11.32 - $16.63 $6.73 Million - $9.89 Million	594,846 Added 979.41%	655,581 $7.47 Million
Q2 2021 Aug 16, 2021	SELL	$15.16 - $18.97 $410,911 - $514,181	-27,105 Reduced 30.86%	60,735 $972,000
Q1 2021 May 17, 2021	SELL	$13.12 - $20.9 $3.47 Million - $5.52 Million	-264,315 Reduced 75.06%	87,840 $1.57 Million
Q4 2020 Feb 16, 2021	SELL	$9.12 - $14.49 $4.55 Million - $7.23 Million	-498,875 Reduced 58.62%	352,155 $4.76 Million
Q3 2020 Nov 16, 2020	SELL	$10.46 - $14.46 $8.96 Million - $12.4 Million	-856,145 Reduced 50.15%	851,030 $10 Million
Q2 2020 Aug 14, 2020	BUY	$12.0 - $16.13 $16.1 Million - $21.7 Million	1,344,538 Added 370.77%	1,707,175 $25.2 Million
Q1 2020 May 15, 2020	SELL	$11.84 - $25.52 $5.56 Million - $12 Million	-469,955 Reduced 56.44%	362,637 $4.9 Million
Q4 2019 Feb 14, 2020	BUY	$17.72 - $25.1 $9.59 Million - $13.6 Million	541,221 Added 185.75%	832,592 $20.1 Million
Q3 2019 Nov 14, 2019	BUY	$18.41 - $28.0 $3.04 Million - $4.62 Million	164,870 Added 130.33%	291,371 $5.6 Million
Q2 2019 Aug 14, 2019	SELL	$28.97 - $48.21 $6.82 Million - $11.3 Million	-235,359 Reduced 65.04%	126,501 $3.74 Million
Q1 2019 May 15, 2019	SELL	$36.32 - $49.25 $42.7 Million - $57.9 Million	-1,176,270 Reduced 76.47%	361,860 $0
Q4 2018 Feb 14, 2019	BUY	$33.0 - $60.04 $4.87 Million - $8.86 Million	147,501 Added 10.61%	1,538,130 $55.5 Million
Q3 2018 Nov 13, 2018	BUY	$56.15 - $73.9 $77.6 Million - $102 Million	1,381,525 Added 15174.92%	1,390,629 $0
Q2 2018 Aug 10, 2018	SELL	$47.85 - $70.45 $98,427 - $144,915	-2,057 Reduced 18.43%	9,104 $0
Q1 2018 May 11, 2018	SELL	$51.15 - $61.0 $1.21 Million - $1.45 Million	-23,742 Reduced 68.02%	11,161 $606,000
Q4 2017 Feb 09, 2018	SELL	$50.85 - $65.1 $8.61 Million - $11 Million	-169,418 Reduced 82.92%	34,903 $2.09 Million
Q3 2017 Nov 09, 2017	BUY	$48.6 - $60.1 $9.93 Million - $12.3 Million	204,321	204,321 $9.93 Million

Others Institutions Holding AERI

# of Institutions

Shares Held

2.4M

Call Options Held

Put Options Held

View Full List

About AERIE PHARMACEUTICALS INC

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

More about AERI

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account